NanoPortal Pipeline Overview

Nano Precision Medical has to date, generally focused on delivering GLP-1 therapies for metabolic diseases such as Type II Diabetes and Non-Alcoholic Steatohepatitis (NASH). These products, while developed for humans, also have applications and markets in other species, such as cats. In addition to the products above, NanoPortal is a platform technology, with potential applications in many disease areas.

GLP-1 Agonists

Proven injectable type 2 diabetes treatment

  • Demonstrated weight-loss

    High GLP-1 levels increases satiety through delayed gastric emptying.

  • Effective glycemic control

    GLP-1 agonists enhance insulin sensitivity and insulin secretion.

  • Safe and effective treatment

    Exenatide was first approved for treating type 2 diabetes in 2005.

Human Type II Diabetes